DSP107

//DSP107
DSP107 2018-10-07T14:37:36+00:00

DSP107
(SIRPα-41BBL)

Discovery
Targeted-immune-activation

Targeted immune activation leading to phagocytic and T-cell mediated tumor destruction

  • CD47 is overexpressed on many cancer cells, and binds SIRPα on phagocytes to produce a “don’t eat me” signal, allowing tumors to evade the immune system
  • 41BB:41BBL interaction provides an immune stimulatory signal
  • DSP107 targets CD47 expressing tumors, blocking the “don’t eat me” signal while simultaneously activating the immune cells via the 41BBL pathway

DSP107 SIRPα-41BBL: Mechanism of Action

SIRPα-41BBL DSP target CD47 overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal

KAHR-107 SIRPα-41BBL: Mechanism of Action
MOA & in-vivo efficacy

MOA & in-vivo efficacy

  • DSP107 targets CD47 overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal
  • Effectively activates 41BB signaling
  • Augments granulocyte mediated phagocytic uptake of tumor cells
  • Activates T cells in the presence of PD-L1 to secrete IFN-γ
CMC development

CMC development

  • CMC development of the human protein initiated
Toxicology: mouse & monkey studies

Clinical development

  • Potential as a therapeutic agent is being evaluated